Gourt > Health > Pharmacy > Drugs and Medications > C > Cisapride
| cis | |
| CAS number 81098-60-4 | ATC code A03FA02 |
| Chemical formula | C23H29ClFN3O4 |
| Molecular weight | 465.9 |
| Bioavailability | ~100% |
| Metabolism | hepatic, intestinal |
| Elimination half life | 10 hours |
| Excretion | renal, biliary |
| Pregnancy category | B1 (Australia) |
| Legal status | Schedule 4 (Australia) |
| Delivery | tablets, suspension |
Clinical uses
Cisapride increases muscle tone in the esophageal sphincter in people with gastroesophageal reflux disease. It also increases gastric emptying in people with diabetic gastroparesis. It has been used to treat bowel constipation.
In many countries it has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias.
More on [ Cisapride ]
Cisapride and Arrhythmias - New Zealand government safety bulletin.
DrugDigest: Cisapride ( Propulsid ) - Information on dosage, usage, side effects, interactions, and drug comparisons.
Medicines Control Agency announces withdrawal of Cisapride - Letter withdrawing Cisapride (Prepulsid) from the UK.
Meta Description: [ The Medicines Control Agency (MCA) today announced the suspension of product licences for cisapride (Prepulsid- Janssen Cilag) with its consequent withdrawal effective from 28 July 2000. ]
Propulsid Warning - Notification of important changes in the U.S. FDA Propulsid labeling to reflect new safety information, including recommendations for performing diagnostics tests prior to any use.
Meta Description: [ DESCRIBE CONTENTS ]
404
Use of Cisapride in Children - A Medical Position Statement of the North American Society for Pediatric Gastroenterology and Nutrition. Discusses the risks and benefits of this medication for treating gastroesophageal reflux and other conditions.
